All In Biotech

Drug Trial Radar · NCT05869669

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 159 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

159

Actual

Start

May 1, 2023

Primary completion

May 29, 2025

Study completion Jun 16, 2025

Sponsor

Lead sponsor
EIP Pharma IncIndustry
Sponsor type
Industry
Collaborators
National Institute on Aging (NIA); Worldwide Clinical Trials; CervoMed, Inc.
First posted
May 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured.

Conditions

  • Dementia With Lewy Bodies

Interventions

  • NeflamapimodDrug

    Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules

  • PlaceboDrug

    Placebo is a capsule that looks just like neflamapimod but without the active ingredients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) in Neflamapimod-treated Participants Compared to Placebo Recipients (Blinded Treatment Period)Time frame: 16 weeks

Locations

40 sites in 3 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Banner Sun Health Research Institute

    Sun City, Arizona

  • Banner Alzheimer's Institute - Edson Family Lewy Body Dementia Center

    Tucson, Arizona

  • UCSD Health Sciences - Movement Disorders Center

    La Jolla, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Stanford Neuroscience Health Center

    Palo Alto, California

  • SC3 Research Group

    Pasadena, California

  • University of Colorado - Dept of Neurology

    Aurora, Colorado

  • Georgetown Univ Hospital - Dept of Neurology

    Washington D.C., District of Columbia

  • JEM Research Institute

    Lake Worth, Florida

  • ClinCloud

    Melbourne, Florida

  • AdventHealth Neuroscience Research

    Orlando, Florida

  • Panhandle Research and Medical Clinic

    Pensacola, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Tandem Clinical Research

    Marrero, Louisiana

  • Johns Hopkins School of Medicine - Dept of Neurology

    Baltimore, Maryland

  • Mass General Hospital/Harvard Medical School - Dept of Neurology

    Charlestown, Massachusetts

  • Mayo Clinic - Alzheimer's Disease Research Center

    Rochester, Minnesota

  • University of Nebraska Medical Center - Dept of Neurological Sciences

    Omaha, Nebraska

  • Cleveland Clinic - Lou Ruvo Center for Brain Health

    Las Vegas, Nevada

  • Columbia University - Taub Institute/Neurology Dept

    New York, New York

  • University of North Carolina - Dept of Neurology

    Chapel Hill, North Carolina

  • NeuroScience Research Center

    Canton, Ohio

  • Cleveland Clinic - Center for Brain Health

    Cleveland, Ohio

  • Ohio State University - Dept of Neurology

    Columbus, Ohio

  • Center for Cognitive Health

    Portland, Oregon

  • Houston Methodist Hospital - Stanley Appel Neurology Dept

    Houston, Texas

  • Sana Research

    Arlington, Virginia

  • Virginia Commonwealth University - Parkinson's and Movement Disorders Center

    Richmond, Virginia

  • Brain Research Center - Den Bosch

    's-Hertogenbosch, Netherlands

  • Brain Research Center - Amsterdam

    Amsterdam, Netherlands

  • Brain Research Center - Zwolle

    Zwolle, Netherlands

  • Belfast Health & Social Care Trust

    Belfast, United Kingdom

  • Cambridgeshire and Peterborough NHS Foundation Trust, Fulbourn Hospital - Windsor Research Unit

    Cambridge, United Kingdom

  • South London and Maudsley NHS Foundation Trust

    London, United Kingdom

  • Re:Cognition Health

    London, United Kingdom

  • University College London (UCL) Clinical Research Facility, University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • Campus Ageing Research Unit (CARU) - Newcastle upon Tyne, CNTW NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

  • Cornwall Partnership NHS Foundation Trust (University of Exeter)

    Redruth, United Kingdom

  • Memory Assessment and Research Centre (MARC) - Moorgreen Hospital

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.